All > Radiotherapy

Immunotherapy for Uveal Melanoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Uveal MelanomaImmunotherapy - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new immunotherapy treatment for cancer that includes two drugs and radiation therapy.

Eligible Conditions
  • Uveal Melanoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
225Ac-J591
1
[111In]-FPI-1547 Injection
1
BMS-986253

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 5 years

5 years
Overall survival
Progression-free survival
Response rate
safety and tolerability of the therapy

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
225Ac-J591
1
[111In]-FPI-1547 Injection
1
BMS-986253

Side Effects for

Omalizumab
20%Injection site reaction
14%Injection site erythema
14%Injection site pruritus
14%Upper respiratory tract infection
12%Nasopharyngitis
10%Injection site swelling
6%Injection site induration
6%Injection site urticaria
5%Headache
5%Pruritus
5%Sinusitis
4%Cough
2%Viral upper respiratory tract infection
1%Asthma
1%Rectal cancer
1%Cellulitis staphylococcal
1%Sexual abuse
1%Abortion induced
This histogram enumerates side effects from a completed 2008 Phase 4 trial (NCT00267202) in the Omalizumab ARM group. Side effects include: Injection site reaction with 20%, Injection site erythema with 14%, Injection site pruritus with 14%, Upper respiratory tract infection with 14%, Nasopharyngitis with 12%.

Trial Design

1 Treatment Group

one arm
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Immunotherapy · No Placebo Group · Phase 2

one armExperimental Group · 2 Interventions: stereotactic body radiotherapy, Immunotherapy · Intervention Types: Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic body radiotherapy
2016
Completed Phase 4
~140
Immunotherapy
2016
Completed Phase 4
~1020

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

California Pacific Medical Center Research InstituteLead Sponsor
41 Previous Clinical Trials
11,636 Total Patients Enrolled
David R Minor, MDStudy ChairCalifornia Pacific Med Center Research Inst.
2 Previous Clinical Trials
36 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have no performance status.
You have no active hepatitis B.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top